Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 19/20 | 0.44 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17615668 | 0.92 | KDM4C (0.47) | KDM4C | |
| SCHEMBL17615737 | 0.87 | KDM4C (0.47) | KDM4C | |
| SCHEMBL17615669 | 0.86 | KDM4C (0.42) | KDM4C | |
| SCHEMBL17615677 | 0.85 | KDM4C (0.48) | KDM4C | |
| SCHEMBL17615665 | 0.85 | KDM4C (0.42) | KDM4C | |
| SCHEMBL17615666 | 0.85 | KDM4C (0.47) | KDM4C | |
| SCHEMBL17615674 | 0.84 | KDM4C (0.46) | KDM4C | |
| SCHEMBL17615662 | 0.83 | KDM4C (0.50) | KDM4C | |
| SCHEMBL17615672 | 0.82 | KDM4C (0.51) | KDM4C | |
| SCHEMBL17602057 | 0.82 | KDM4C (0.63) | KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117519-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-11535616-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC (US) | 2022-12-27 | — | — | US | disclosed |
| US-20210009585-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-10815234-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-20200199122-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-06-25 | — | — | US | disclosed |
| US-10208039-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-10202381-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20190023704-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-01-24 | — | — | US | disclosed |
| US-10030017-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10030017-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20180162857-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162857-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20170240546-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170240546-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-08-24 | — | — | US | disclosed |
| US-9643965-B2 | Histone demethylase inhibitors | Celgene Quantical Research, Inc. (US) | 2017-05-09 | — | — | US | disclosed |
| US-9643965-B2 | Histone demethylase inhibitors | Celgene Quantical Research, Inc. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20160194323-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160194323-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160083379-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20160083379-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194323-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5C, KDM1A | KDM4C 9/4885CXCR2 4360/4885 |
| US-10030017-B2 | Histone demethylase inhibitors | KDM1B, KDM5C, KDM1A | KDM4C 9/4885CXCR2 4360/4885 |
| US-20160083379-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | KDM4C 9/4885CXCR2 4366/4885 |
| US-11535616-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM5C | KDM4C 9/4885CXCR2 4366/4885 |
| US-20170240546-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | KDM4C 9/4885CXCR2 4366/4885 |
| US-20190023704-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | KDM4C 9/4885CXCR2 4366/4885 |
| US-20200199122-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | KDM4C 9/4885CXCR2 4366/4885 |
| US-20180162857-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5C, KDM1A | KDM4C 9/4885CXCR2 4360/4885 |
| US-20230117519-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | KDM4C 9/4885CXCR2 4366/4885 |
| US-10202381-B2 | Histone demethylase inhibitors | KDM1B, KDM5C, KDM1A | KDM4C 9/4885CXCR2 4360/4885 |
| US-20210009585-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | KDM4C 9/4885CXCR2 4366/4885 |
| US-10815234-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM5C | KDM4C 9/4885CXCR2 4366/4885 |
| US-10208039-B2 | Histone demethylase inhibitors | KDM1B, KDM5C, KDM1A | KDM4C 9/4885CXCR2 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.